Literature DB >> 31797529

Fair-Weather Friends: Evidence of Lipoxin Dysregulation in Neurodegeneration.

Changmo Kim1,2,3, Izhar Livne-Bar1,2,3, Karsten Gronert4,5, Jeremy M Sivak1,2,3.   

Abstract

Lipoxins (LXs) are autacoids, specialized proresolving lipid mediators (SPMs) acting locally in a paracrine or autocrine fashion. They belong to a complex superfamily of dietary small polyunsaturated fatty acid (PUFA)-metabolites, which direct potent cellular responses to resolve inflammation and restore tissue homeostasis. Together, these SPM activities have been intensely studied in systemic inflammation and acute injury or infection, but less is known about LX signaling and activities in the central nervous system. LXs are derived from arachidonic acid, an omega-6 PUFA. In addition to well-established roles in systemic inflammation resolution, they have increasingly become implicated in regulating neuroinflammatory and neurodegenerative processes. In particular, chronic inflammation plays a central role in Alzheimer's disease (AD) etiology, and dysregulated LX production and activities have been reported in a variety of AD rodent models and clinical tissue samples, yet with complex and sometimes conflicting results. In addition, reduced LX production following retinal injury has been reported recently by the authors, and an intriguing direct neuronal activity promoting survival and homeostasis in retinal and cortical neurons is demonstrated. Here, the authors review and clarify this growing literature and suggest new research directions to further elaborate the role of lipoxins in neurodegeneration.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Alzheimer's disease; arachidonic acid (AA); glaucoma; lipoxins; neurodegeneration; neuroinflammation; poly-unsaturated fatty acids (PUFAs)

Mesh:

Substances:

Year:  2020        PMID: 31797529      PMCID: PMC8691368          DOI: 10.1002/mnfr.201801076

Source DB:  PubMed          Journal:  Mol Nutr Food Res        ISSN: 1613-4125            Impact factor:   5.914


  95 in total

Review 1.  Glia in mammalian development and disease.

Authors:  J Bradley Zuchero; Ben A Barres
Journal:  Development       Date:  2015-11-15       Impact factor: 6.868

2.  Biomechanical insult switches PEA-15 activity to uncouple its anti-apoptotic function and promote erk mediated tissue remodeling.

Authors:  Rachel E Exler; Xiaoxin Guo; Darren Chan; Izhar Livne-Bar; Nevena Vicic; John G Flanagan; Jeremy M Sivak
Journal:  Exp Cell Res       Date:  2015-11-23       Impact factor: 3.905

3.  Transcriptional regulation of β-secretase-1 by 12/15-lipoxygenase results in enhanced amyloidogenesis and cognitive impairments.

Authors:  Jin Chu; Jia-Min Zhuo; Domenico Praticò
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

4.  Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent.

Authors:  Fabiana S Machado; James E Johndrow; Lisia Esper; Alexandra Dias; Andre Bafica; Charles N Serhan; Julio Aliberti
Journal:  Nat Med       Date:  2006-01-15       Impact factor: 53.440

5.  Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo.

Authors:  C B Clish; J A O'Brien; K Gronert; G L Stahl; N A Petasis; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 6.  Lipoxins: resolutionary road.

Authors:  Paola Maderna; Catherine Godson
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

7.  Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1.

Authors:  Y Le; W Gong; H L Tiffany; A Tumanov; S Nedospasov; W Shen; N M Dunlop; J L Gao; P M Murphy; J J Oppenheim; J M Wang
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

Review 8.  Pro-resolving lipid mediators are leads for resolution physiology.

Authors:  Charles N Serhan
Journal:  Nature       Date:  2014-06-05       Impact factor: 49.962

9.  Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.

Authors:  Marian Goicoechea; Maria Dolores Sanchez-Niño; Alberto Ortiz; Soledad García de Vinuesa; Borja Quiroga; Carmen Bernis; Enrique Morales; Gema Fernández-Juarez; Patricia de Sequera; Ursula Verdalles; Eduardo Verde; José Luño
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2017-08-24       Impact factor: 4.006

10.  NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival.

Authors:  J M Calandria; A Asatryan; V Balaszczuk; E J Knott; B K Jun; P K Mukherjee; L Belayev; N G Bazan
Journal:  Cell Death Differ       Date:  2015-01-30       Impact factor: 15.828

View more
  3 in total

Review 1.  Could Arachidonic Acid-Derived Pro-Resolving Mediators Be a New Therapeutic Strategy for Asthma Therapy?

Authors:  Daniella Bianchi Reis Insuela; Maximiliano Ruben Ferrero; Diego de Sá Coutinho; Marco Aurélio Martins; Vinicius Frias Carvalho
Journal:  Front Immunol       Date:  2020-12-09       Impact factor: 7.561

Review 2.  Lipoxins in the Nervous System: Brighter Prospects for Neuroprotection.

Authors:  Jiayu Zhang; Zhe Li; Mingyue Fan; Wei Jin
Journal:  Front Pharmacol       Date:  2022-01-26       Impact factor: 5.810

Review 3.  Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?

Authors:  Keishi Miyazawa; Hisanori Fukunaga; Yasuko Tatewaki; Yumi Takano; Shuzo Yamamoto; Tatsushi Mutoh; Yasuyuki Taki
Journal:  Int J Mol Sci       Date:  2020-08-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.